Company profile
Akebia Therapeutics, Inc.
NASDAQ: AKBA · Healthcare · Biotechnology
#279 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
66BFH 63DQ 76GM 57SS 66
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ 3-yr revenue growth, balance-sheet leverage
Methodology →Revenue TTM
$232.4M
Rev growth YoY (TTM)
+25.7%
Net income (FY)
-$5.3M
Employees
194
as of 2026-08-12
Market cap
$232.4M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$236.2M$236.2M2025
Net income-$5.3M-$5.3M2025
Operating income$23.5M$23.5M2025
Total assets$376.6M$376.6M2025
Liabilities$344.0M$344.0M2025
Equity$32.6M$32.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License Collaboration And Other Revenue96%
Supply Agreement3%
License Collaboration And Other Revenue, Royalties1%
By geography
Not disclosed.
The read
What is Akebia Therapeutics, Inc.’s revenue?
Akebia Therapeutics, Inc. booked $236.2M in FY2025 revenue, growing 47% year over year — faster than most Healthcare companies we track, at a -2.3% net margin.
Peers · Healthcare
STAAR Surgical Company67BVaxart, Inc.72BOrthoPediatrics Corp.69BAnaptysBio, Inc.75B+Cerus Corporation74BTalkspace, Inc.71BNeighbors
Middlesex →Key facts
CEOJohn Butler
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: AKBA
Employees194
IPO date2014-03-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.